Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration clearance of its Investigational New Drug application for Lucid-MS, enabling the company to proceed with a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis. This regulatory milestone marks a significant step for a first-in-class therapy that takes a different approach from existing MS treatments.
Lucid-MS is a patented, non-covalent inhibitor of peptidyl arginine deiminase 2, an enzyme implicated in myelin degradation. Rather than suppressing the immune system—the mechanism of most current MS therapies—Lucid-MS aims to directly prevent and reverse demyelination, the underlying cause of MS progression. This novel mechanism could offer benefits to patients who do not respond adequately to immunomodulatory drugs or who experience significant side effects.
The FDA's clearance of the IND application is a critical regulatory hurdle that allows Quantum BioPharma to initiate human testing of Lucid-MS. The planned phase 2 trial will assess the drug's efficacy and safety in MS patients. Positive results could position Lucid-MS as a transformative treatment option in a market where many therapies only slow disease progression rather than repair damage.
Quantum BioPharma is also collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination. This collaboration could provide valuable biomarkers for assessing treatment response and further validate Lucid-MS's mechanism of action.
The company's progress comes amid a broader wave of innovation in neurological and oncological therapies, with several major pharmaceutical firms advancing their own pipelines. For example, Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia, and Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma.
For Quantum BioPharma, the advancement of Lucid-MS represents a potential paradigm shift in MS treatment. If successful, the drug could address a major unmet need by targeting the root cause of disability rather than just managing symptoms. The company also holds other assets, including UNBUZZD™, an over-the-counter product spun out to Unbuzzd Wellness Inc., in which Quantum retains a 19.84% ownership stake and royalty rights.
Investors and patients alike will be watching closely as Quantum BioPharma moves Lucid-MS into the clinic. The phase 2 trial will be a key test of whether this innovative approach can deliver on its promise. For more information, visit the full press release at https://ibn.fm/lCey9.
